BioCentury | Feb 28, 2020

Biogen expands its modality toolkit in Alzheimer’s and Parkinson’s with Sangamo deal

...rights to three preclinical zinc finger protein transcription factors (ZFP-TFs) from Sangamo Therapeutics Inc. (NASDAQ:SGMO): ST-501...
...blockage of tau. At its R&D day in December, Sangamo presented preclinical data from the ST-501...
Items per page:
1 - 1 of 1